Clearside Biomedical shares fall 61.76% premarket after filing Chapter 11 bankruptcy in US.

Clearside Biomedical’s stock plummeted 61.76% in premarket trading following its Chapter 11 bankruptcy filing in the U.S., as disclosed in court documents. The company, which develops suprachoroidal injection therapies for retinal diseases, listed estimated assets between $1 million–$10 million and liabilities between $50 million–$100 million. The bankruptcy announcement, a direct bearish catalyst, triggered severe investor skepticism amid concerns over liquidity and operational viability. The premarket selloff reflects the market’s immediate reaction to the company’s insolvency, aligning with the magnitude of the disclosed financial imbalance.